CompletedPhase 2

Buccal Film Versus IV Injection Palonosetron for Moderately Emetogenic Chemotherapy Induced Nausea and Vomiting

United States22 participantsStarted 2020-10-01

Plain-language summary

Phase 2 study to compare efficacy, safety and PK of palonosetron, a long acting 5-HT3 receptor antagonist, by buccal film delivery compared to iv injection for chemotherapy induced nausea or vomiting (CINV). Subjects receive a single dose of palonosetron prior to moderately emetogenic chemotherapy.

Who can participate

Age range18 Years

SexALL

See this in plain English?

AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.

Inclusion criteria

✓. Be scheduled to receive the first course of MEC to be administered on Day 1

What they're measuring

Complete Acute Response

Timeframe: first 24 hours after chemotherapy

Trial details

NCT IDNCT04592198

SponsorXiamen LP Pharmaceutical Co., Ltd

Sponsor typeINDUSTRY

Study typeINTERVENTIONAL

Primary completion2021-03-25

Results submitted2025-01-24

View on ClinicalTrials.gov More Nausea With Vomiting Chemotherapy-Induced trials